Good news gives a healthy boost to Astrazeneca
ASTRAZENECA got a double immune boost yesterday as one of its drugs was given orphan status in the US, while trials of a three-drug inhaler showed good results against a pulmonary disease caused by smoking.
The firm said its medicine Fasenra was granted special status as an orphan drug in the US. Orphans are medicines that treat rare diseases.
Fasenra treats eosinophilic oeso-phagitis, a chronic disease that causes injury and inflammation in the oesophagus.
The category is desi...